Design Therapeutics Analyst Ratings
Design Therapeutics Analyst Ratings
Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
---|---|---|---|---|---|
08/15/2023 | -4.5% | RBC Capital | $23 → $7 | Downgrades | Outperform → Sector Perform |
05/10/2023 | 213.78% | RBC Capital | $24 → $23 | Maintains | Outperform |
05/10/2023 | 159.21% | Wedbush | $20 → $19 | Maintains | Outperform |
05/04/2023 | — | Goldman Sachs | Upgrades | Sell → Neutral | |
03/15/2023 | 227.42% | RBC Capital | → $24 | Reiterates | → Outperform |
12/09/2022 | 200.14% | SVB Leerink | $30 → $22 | Maintains | Outperform |
12/08/2022 | 227.42% | RBC Capital | $29 → $24 | Maintains | Outperform |
08/09/2022 | 254.71% | Wedbush | $21 → $26 | Maintains | Outperform |
06/10/2022 | 186.49% | Wedbush | → $21 | Initiates Coverage On | → Outperform |
05/24/2022 | -18.14% | Goldman Sachs | $8 → $6 | Maintains | Sell |
05/10/2022 | 309.28% | SVB Leerink | $36 → $30 | Maintains | Outperform |
05/02/2022 | 309.28% | RBC Capital | → $30 | Initiates Coverage On | → Outperform |
01/19/2022 | 36.43% | Goldman Sachs | → $10 | Initiates Coverage On | → Sell |
04/20/2021 | 391.13% | SVB Leerink | → $36 | Initiates Coverage On | → Outperform |
04/20/2021 | 281.99% | Goldman Sachs | → $28 | Initiates Coverage On | → Neutral |
04/20/2021 | 472.99% | Piper Sandler | → $42 | Initiates Coverage On | → Overweight |
日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
---|---|---|---|---|---|
08/15/2023 | -4.5% | 加拿大皇家银行资本 | 23 美元 → 7 美元 | 降级 | 跑赢大盘 → 行业表现 |
05/10/2023 | 213.78% | 加拿大皇家银行资本 | 24 美元 → 23 美元 | 维护 | 跑赢大盘 |
05/10/2023 | 159.21% | Wedbush | 20 美元 → 19 美元 | 维护 | 跑赢大盘 |
05/04/2023 | — | 高盛 | 升级 | 卖出 → 中立 | |
03/15/2023 | 227.42% | 加拿大皇家银行资本 | → 24 美元 | 重申 | → 跑赢大盘 |
2022 年 9 月 12 日 | 200.14% | SVB Leerink | 30 美元 → 22 美元 | 维护 | 跑赢大盘 |
2022 年 8 月 12 日 | 227.42% | 加拿大皇家银行资本 | 29 美元 → 24 美元 | 维护 | 跑赢大盘 |
08/09/2022 | 254.71% | Wedbush | 21 美元 → 26 美元 | 维护 | 跑赢大盘 |
06/10/2022 | 186.49% | Wedbush | → 21 美元 | 启动覆盖开启 | → 跑赢大盘 |
2022 年 5 月 24 日 | -18.14% | 高盛 | 8 美元 → 6 美元 | 维护 | 卖出 |
05/10/2022 | 309.28% | SVB Leerink | 36 美元 → 30 美元 | 维护 | 跑赢大盘 |
05/02/2022 | 309.28% | 加拿大皇家银行资本 | → 30 美元 | 启动覆盖开启 | → 跑赢大盘 |
2022 年 1 月 19 日 | 36.43% | 高盛 | → 10 美元 | 启动覆盖开启 | → 卖出 |
04/20/2021 | 391.13% | SVB Leerink | → 36 美元 | 启动覆盖开启 | → 跑赢大盘 |
04/20/2021 | 281.99% | 高盛 | → 28 美元 | 启动覆盖开启 | → 中立 |
04/20/2021 | 472.99% | 派珀·桑德勒 | → 42 美元 | 启动覆盖开启 | → 超重 |
What is the target price for Design Therapeutics (DSGN)?
Design Therapeutics(DSGN)的目标价格是多少?
The latest price target for Design Therapeutics (NASDAQ: DSGN) was reported by RBC Capital on August 15, 2023. The analyst firm set a price target for $7.00 expecting DSGN to fall to within 12 months (a possible -4.50% downside). 7 analyst firms have reported ratings in the last year.
加拿大皇家银行资本于2023年8月15日公布了Design Therapeutics(纳斯达克股票代码:DSGN)的最新目标股价。这家分析公司将目标股价定为7.00美元,预计DSGN将在12个月内跌至-4.50%(可能下跌-4.50%)。去年有7家分析公司公布了评级。
What is the most recent analyst rating for Design Therapeutics (DSGN)?
分析师对Design Therapeutics(DSGN)的最新评级是多少?
The latest analyst rating for Design Therapeutics (NASDAQ: DSGN) was provided by RBC Capital, and Design Therapeutics downgraded their sector perform rating.
Design Therapeutics(纳斯达克股票代码:DSGN)的最新分析师评级由加拿大皇家银行资本提供,Design Therapeutics下调了其行业表现评级。
When is the next analyst rating going to be posted or updated for Design Therapeutics (DSGN)?
Design Therapeutics(DSGN)的下一个分析师评级何时公布或更新?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Design Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Design Therapeutics was filed on August 15, 2023 so you should expect the next rating to be made available sometime around August 15, 2024.
分析师在进行了广泛的研究后得出了股票评级,其中包括浏览公开财务报表,与Design Therapeutics的高管和客户交谈,以及听取财报电话会议。大多数分析师每三个月进行一次评级,因此每家公司每年应该获得4个评级。Design Therapeutics的最新评级是在2023年8月15日提交的,因此你应该预计下一个评级将在2024年8月15日左右公布。
Is the Analyst Rating Design Therapeutics (DSGN) correct?
分析师评级 Design Therapeutics (DSGN) 是否正确?
While ratings are subjective and will change, the latest Design Therapeutics (DSGN) rating was a downgraded with a price target of $23.00 to $7.00. The current price Design Therapeutics (DSGN) is trading at is $7.33, which is out of the analyst's predicted range.
尽管评级是主观的,将会发生变化,但最新的Design Therapeutics(DSGN)评级被下调,目标股价为23.00美元至7.00美元。Design Therapeutics(DSGN)目前的交易价格为7.33美元,超出了分析师的预测区间。